Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Microbot Medical ( (MBOT) ).
On September 14, 2025, Microbot Medical Inc. entered into an inducement agreement with certain holders to exercise existing preferred investment options, resulting in the issuance of new series J preferred investment options. The first closing occurred on September 16, 2025, with gross proceeds of approximately $25.2 million, and a second closing is expected by October 15, 2025, with anticipated proceeds of $4.0 million. The company plans to use the net proceeds for the development and commercialization of its LIBERTY® Robotic System, potential acquisitions, and other corporate purposes. This transaction reflects Microbot’s strategic efforts to secure funding for its innovative medical technologies and expand its market presence.
The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a breakthrough medical device company focused on transforming endovascular procedures through advanced robotic technology. The company’s flagship product, the LIBERTY® Endovascular Robotic System, is the first single-use, remotely operated robotic solution designed for precision, efficiency, and provider safety. Microbot Medical is committed to innovation and holds a strong intellectual property portfolio, positioning itself at the forefront of endovascular care.
Average Trading Volume: 3,391,784
Technical Sentiment Signal: Buy
Current Market Cap: $155.8M
For an in-depth examination of MBOT stock, go to TipRanks’ Overview page.